Literature DB >> 28209332

Approved drugs for multiple sclerosis: the challenge of choice.

Maria Pia Sormani1, Alice Laroni2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28209332     DOI： 10.1016/S1474-4422(17)30021-2

Source DB:  PubMed          Journal:  Lancet Neurol        ISSN： 1474-4422            Impact factor:   44.182


× No keyword cloud information.
  3 in total

Review 1.  Molecular Magnetic Resonance Imaging of Endothelial Activation in the Central Nervous System.

Authors:  Maxime Gauberti; Antoine P Fournier; Fabian Docagne; Denis Vivien; Sara Martinez de Lizarrondo
Journal:  Theranostics       Date:  2018-02-02       Impact factor: 11.556

2.  Neurological update: treatment escalation in multiple sclerosis patients refractory to fingolimod-potentials and risks of subsequent highly active agents.

Authors:  Melanie Korsen; Steffen Pfeuffer; Leoni Rolfes; Sven G Meuth; Hans-Peter Hartung
Journal:  J Neurol       Date:  2022-01-09       Impact factor: 6.682

3.  Impact of previous disease-modifying treatment on effectiveness and safety outcomes, among patients with multiple sclerosis treated with alemtuzumab.

Authors:  Steffen Pfeuffer; Tobias Ruck; Heinz Wiendl; Sven G Meuth; Refik Pul; Leoni Rolfes; Catharina Korsukewitz; Marc Pawlitzki; Brigitte Wildemann; Luisa Klotz; Christoph Kleinschnitz; Antonio Scalfari
Journal:  J Neurol Neurosurg Psychiatry       Date:  2021-03-12       Impact factor: 10.154
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.